ETD001
Cystic Fibrosis
Phase 1Active
Key Facts
About Enterprise Therapeutics
Enterprise Therapeutics is a private, clinical-stage biotech founded in 2015 and headquartered in Brighton, UK, targeting major respiratory diseases. Its core strategy involves developing small molecule therapies that address mucus congestion, a key pathological feature in cystic fibrosis, asthma, and COPD. The company's lead asset, ETD001, has completed a Phase 1 study and received Rare Pediatric Disease Designation in the US, marking significant progress. Backed by a syndicate of leading life science investors, Enterprise is advancing its pipeline toward later-stage clinical development.
View full company profileTherapeutic Areas
Other Cystic Fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| CB-280 | Calithera Biosciences | Preclinical/Phase 1 |
| Ensifentrine | Verona Pharma | Phase 2 |
| ALTA Drug Series | Alteron Therapeutics | Preclinical |
| ColiFin® | Spexis | Marketed (EU) |
| Cystic fibrosis (CRISPR) | GeneToBe | Discovery |
| Cystic fibrosis (undisclosed) | GeneToBe | Early Discovery |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| Targeted Lung Delivery | Nanite | Pre-clinical |
| CFTR 100+ Panel | Agena Bioscience | Commercial |
| RIG-301 CFTR | RIGImmune | Pre-clinical |
| CBN-101 | Carbon Biosciences | Preclinical |
| RESP® Biosensor Evaluation (with Rutgers Health) | Strados Labs | Research Study |